Actionable news
All posts from Actionable news

Entry into a Material Definitive


On April 25, 2016, we entered into Amendment No. 1 (the Amendment) to Loan and Security Agreement with Hercules Capital, Inc. Under the Amendment, the scheduled principal payments due May 1, 2016 and the first business day of each month thereafter through and including the payment due on May 1, 2017 under the loan agreement will be deferred, and we will make interest-only payments during that period. Regular payments of principal and interest will commence on June 1, 2017. As of April 25, 2016, the outstanding principal amount under the loan agreement was approximately $12.8 million.

Item 5.02


Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers


On April 25, 2016, we awarded Dr. Lawrence Mayer, our President and Chief Scientific Officer a special one-time bonus as a founder of the company in the amount of $118,580 (CDN$).

Item 9.01


Financial Statements and Exhibits


Exhibit No.

Exhibit Description


Amendment No. 1 to Loan and Security Agreement dated April 25, 2016 among Celator Pharmaceuticals, Inc., Celator Pharmaceuticals Corp. and Hercules Capital, Inc.


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.



/s/ Fred M. Powell

Fred M. Powell,

Vice President and Chief Financial Officer

makes a similar move, sign up!

Other recent filings from the company include the following:

Wayne Holman just provided an update on share ownership of Celator Pharmaceuticals Inc - April 27, 2016
Scott Morenstein just provided an update on activist position in Celator Pharmaceuticals Inc - April 22, 2016
Departure of Directors or Certain - April 5, 2016